Archive for the ‘Lymphoma / Leukemia’ Category
Tuesday, December 11th, 2007
Many primary care physicians may lack the necessary knowledge when it comes to recognizing the signs, symptoms and making proper diagnoses in cases of blood cancers such as leukemia and lymphoma, a recent survey indicates.But co-author Richard Wender, M.D., professor and chair of Family and Community Medicine at Jefferson Medical ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, December 11th, 2007
Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, December 11th, 2007
Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).This drug candidate could build on the legacy of Gleevec, which has been the gold standard for treating this leukemia and was developed ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, December 11th, 2007
Celator Pharmaceuticals announced results from an ongoing Phase I study of CPX-351, a liposomal formulation that incorporates a synergistic ratio of cytarabine and daunorubicin for the treatment of advanced leukemias and myelodysplastic syndromes. While dose escalation in the study is ongoing, thus far three patients treated with CPX-351 have ...
Posted in Lymphoma / Leukemia | No Comments »
Monday, December 10th, 2007
New data from the largest clinical trial in newly diagnosed patients with a life-threatening form of leukemia showed that long-term use of Gleevec® (imatinib mesylate) tablets can halt progression to advanced disease stages in the sixth year of treatment. Results of the International Randomized Interferon versus STI571 (IRIS) study reveal ...
Posted in Lymphoma / Leukemia | No Comments »
Tuesday, December 4th, 2007
People who undergo nonmyeloablative stem-cell transplants, or "mini transplants," for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.The research by Marco Mielcarek, M.D., ...
Posted in Lymphoma / Leukemia | No Comments »
Monday, December 3rd, 2007
INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) announced that the first patient has been treated in a pivotal Phase II clinical trial evaluating oral Tamibarotene for the treatment of refractory acute promyelocytic leukemia (APL). APL is a type of acute myeloid leukemia. This trial will be conducted under a Special Protocol Assessment (SPA) ...
Posted in Lymphoma / Leukemia | No Comments »
Monday, November 12th, 2007
Seattle Genetics, Inc. (Nasdaq:SGEN) announced that it has initiated a phase IIb clinical trial of SGN-33 (lintuzumab), a monoclonal antibody, in combination with a low-dose regimen of the chemotherapeutic agent cytarabine for patients with acute myeloid leukemia (AML). The randomized, double-blind, placebo-controlled study is designed to assess whether this combination ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, November 8th, 2007
The drug imatinib mesylate, more commonly known as Gleevec(R), proves safe and effective over the long term in patients with an advanced form of chronic myeloid leukemia (CML), according to a study prepublished online in Blood, the official journal of the American Society of Hematology. A team of researchers ...
Posted in Lymphoma / Leukemia | No Comments »
Thursday, November 1st, 2007
The U.S. Food and Drug Administration (FDA) has approved Tasigna (nilotinib) capsules for treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients whose disease has progressed on or who cannot tolerate other therapies that included imatinib. Imatinib (Gleevec) is approved for the treatment of new diagnosed patients ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, October 19th, 2007
Abraxis Pharmaceutical Products (APP), the hospital-based business of Abraxis BioScience, Inc. (NASDAQ:ABBI), announced two approvals from U.S. Food and Drug Administration (FDA) to market the liquid and lyophilized versions of Fludarabine phosphate. The lyophilized version of fludarabine, which is the generic equivalent of Fludara® (fludarabine phosphate) for injection distributed by ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, October 19th, 2007
In the November 1st issue of G&D, Dr. Michael Cleary (Stanford University School of Medicine) and colleagues identify the gene Meis1 as a critical player in the establishment of leukemia stem cells, and the development of MLL leukemia.Mixed lineage leukemia (MLL) is a distinctive type of leukemia -- distinguished from ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, October 19th, 2007
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced publication, for the first time, of the high-resolution structure of the protein responsible for one of the major clinically relevant genetic variants of drug-resistant chronic myeloid leukemia (CML). These findings by a team of ARIAD scientists were used to guide the design of ARIAD's ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, October 19th, 2007
EbpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) reported that the assessment of its European Union centralized marketing authorization application for its lead oncology product Ceplene(TM) is advancing according to the anticipated regulatory timetable following a meeting yesterday. Ceplene (histamine dihydrochloride) has demonstrated important clinical benefit in the ...
Posted in Lymphoma / Leukemia | No Comments »
Friday, October 19th, 2007
IPSOGEN, a leading molecular diagnostic company based in France and Connecticut, announced that it has signed a co-exclusive license agreement with XENOMICS (Pink Sheets: XNOM), a developer of next-generation medical DNA diagnostic technologies, based in USA. The license enables IPSOGEN to develop, manufacture and commercialize research and diagnostic products ...
Posted in Lymphoma / Leukemia | No Comments »
